Antiplatelet Drugs has 6 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alteplase, Tirofiban, Tirofiban Hydrochloride. Patients taking Antiplatelet Drugs should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 4
- Moderate
- 2
Major (4)
- Antiplatelet Drugs + Alteplase— Antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Alteplase therapy.
- Antiplatelet Drugs + Tirofiban— Concomitant use increases the risk of bleeding.
- Antiplatelet Drugs + Tirofiban Hydrochloride— Concomitant use increases the risk of bleeding.
- Antiplatelet Drugs + Venlafaxine Hydrochloride— Concomitant use may potentiate bleeding risk. Monitor closely for bleeding.
Moderate (2)
- Antiplatelet Drugs + Venlafaxine— Concomitant use may potentiate the risk of bleeding. Monitor patients closely for bleeding when initiating or discontinu…
- Antiplatelet Drugs + Venlafaxine Hcl Er— Concomitant use may potentiate bleeding risk. Closely monitor for bleeding when initiating or discontinuing venlafaxine.